Novo blinked.
Edition #1 is on the way. Subscribe and it lands in your inbox the moment it publishes.
The GLP-1 economy, explained in 5 minutes.
Twice a week: drug prices, the Lilly vs Novo war, generic launches, and what the biggest drugs in the world are doing to money and culture. Free, sharp, no fluff.
subscribedCheck your inbox to confirm. The next brief lands Tuesday.
Join readers from health, finance, and the couch. Unsubscribe anytime.
What you get
Prices, tracked.
Every launch, list price, and generic step, with the numbers verified.
The war, called.
Lilly, Novo, and the challengers, covered like the title fight it is.
The ripple, reported.
What GLP-1s are doing to food, fitness, insurance, and everything downstream.
the signature column
Dispatches from the post-patent future.
Canada broke the semaglutide patents first. Generic pens are already$88 a month there. We report from the aftermath so you can see what is coming everywhere else.